Asimov and Emergent Biosolutions Announce Cell Line Development Partnership to Advance Novel Antibodies Against Ebola
Emergent BioSolutions to Participate in Jefferies Global Healthcare Conference
Emergent BioSolutions: A Turnaround Still Waiting For Consistent Execution
Emergent BioSolutions Inc (EBS) (Q3 2026) Earnings Call Highlights: Revenue Timing Weighs on ...
Emergent BioSolutions Inc. Receives $22.3 million Delivery Order Modification to Supply BioThrax
Emergent BioSolutions Receives $22.3 Million Delivery Order Modification to Supply BioThrax® (Anthrax Vaccine Adsorbed) to the U.S. Department of War
Emergent BioSolutions Awarded $22.3M Contract Modification To Provide BioThrax To U.S. Department Of War
Emergent BioSolutions Inc. Q3 2026 Earnings Call Summary
Emergent BioSolutions: 3 Key Takeaways for Long-Term Investors
Emergent BioSolutions (EBS) Q3 2026 Earnings Call Transcript
Emergent Biosolutions: Q3 Earnings Snapshot
Emergent BioSolutions Inc. 2026 Q3 - Results - Earnings Call Presentation
Emergent BioSolutions (NYSE:EBS) Shares Fall as Q3 2026 Revenue Misses and Adjusted EBITDA Turns Negative
Emergent Biosolutions Q3 Earnings Call Highlights
Emergent BioSolutions Inc. (EBS) Q3 2026 Earnings Call Transcript
Emergent Biosolutions Reports Third Quarter 2026 Financial Results
Emergent BioSolutions Q3 2026 Earnings Call Transcript
Emergent BioSolutions Lowers FY2026 Sales Guidance from $645.000M-$675.000M to $600.000M-$645.000M vs $657.133M Est
Emergent BioSolutions Q3 Adj. EPS $(0.36) Beats $(0.39) Estimate, Sales $110.000M Miss $123.200M Estimate
Emergent BioSolutions stock falls as CFO plans retirement
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.